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hor’s reply We  agree that the obesity paradox after PCI is controversial and
that further study is needed to resolve this controversy. Moreover,Thank you for the intellectual comments. It is my  great honor
nswer the problems that Dr Lin suggested and to have such a
tful discussion.
We agreed with Dr Lin that the impact of body-mass index (BMI)
 obesity on the clinical outcomes of the coronary artery disease
due to sophisticated patient care and the improved prognosis of
CAD patients, the obesity-mortality paradox may  be attenuated
in future. However, we also believe that the obesity paradox is
still applicable to particular subjects with CAD after PCI. We  think
that it is more important to clarify such patients and to explain
the
and
tiss
eve
pat
of t
[3]
TN
sub
Pro
has
CAD
wa
ma
dep
ass
ﬁel
sity
sug
lec
to h
Ref
[1] 
[2] 
[3] 
[4] 
[5] 
Available online 2 November 2013D) patients treated with percutaneous coronary intervention
I) was controversial and the impact of BMI  would differ accord-
 to the study population and focused clinical events.
According to the suggestion, we analyzed the impact of the
I  category on the short-term (≤1 year) and the long-term (>1
r) clinical outcomes after PCI. As a result, the BMI  category was
iﬁcantly associated with not only the short-term but also the
g-term mortality after PCI in our registry. Furthermore, obese
jects tended to have lower risk of cardiovascular death and sig-
cantly lower risk of heart failure admission. Because of the small
ple size and limited follow-up periods, we could not evaluate
 impact of BMI  on very long-term (more than 5 years) clinical
comes after PCI in our registry. Further study is needed to clar-
this point. However, a J-shaped relationship between BMI  and
rtality rate was not seen in the chronic phase after PCI in the
ow-up period of our registry.
Next, we would like to answer the question regarding bare metal
t (BMS) and drug-eluting stent (DES) use. In the present study,
S  were implanted in 33%, whereas DES were implanted in 65% of
dy patients. According to the comments, we divided the patients
 the BMS-treated group and the DES-treated group, and ana-
d the impact of the BMI  category on the long-term mortality,
pectively. Kaplan–Meier curves and the log-rank test revealed
t obese patients had signiﬁcantly lower incidences of all-cause
th both in the BMS-treated group and the DES-treated group.
Dr Lin mentioned, the obesity-mortality paradox seemed to
attenuated in patients treated with DES. However, we think
t this phenomenon is mainly caused by the fact that BMS  were
cted in patients with acute coronary syndrome, whereas DES
re selected in patients with stable angina pectoris in our clinical
ctice. Dr Lin referred to the work by Wang et al., demonstrat-
 that obese patients had a higher risk for long-term clinical
comes following PCI with DES [1]. However, the endpoint of
 article was the composite of cardiovascular thrombotic events,
luding cardiac death and non-fatal myocardial infarction, there-
 this paper did not evaluate the obesity-mortality (all-cause
rtality) paradox after PCI. Moreover, patients with older age,
elevation myocardial infarction, severe renal dysfunction, and
r history of revascularization therapy, etc., were excluded in
 study by Wang et al. In contrast, our registry included all CAD
ients treated with PCI [2], which might account for the differ-
es of the results between our study and those of Wang et al.
sidering this point, patient selection and endpoint setting is
ortant when we compare the results of the different studies
 discuss the obesity paradox after PCI.
As we described in the original paper, we recognize that our
dy has several limitations. This study is based on a single center’s
erience, and the number of study patients was small. There-
, the results cannot be generalized to all medical centers. As
 lean patients were older and had higher frequency of chronic
ney disease, it might be possible that the lean patients had more
ere CAD. Further study is required to clarify the association of severity of CAD and the obesity paradox after PCI. http mechanisms of obesity paradox. A causal link between obesity
 improved clinical outcomes is biologically plausible. Adipose
ue is increasingly recognized as an active endocrine organ, how-
r, the effects of adipokines on CAD remain unclear. Among
ients with heart failure (HF), obese subjects have lower levels
umor necrosis factor (TNF) and other inﬂammatory cytokines
. Interestingly, increased adipose tissue production of soluble
F receptors, which is believed to neutralize TNF- [4] in obese
jects might have a cardioprotective effect in patients with HF.
duction of leptin is increased in obese subjects, and leptin
 previously been implicated as an independent risk factor for
. On the other hand, Momin  et al. demonstrated that leptin
s a vasoactive peptide in human saphenous vein and internal
mmary artery and its action was not nitric oxide or endothelial-
endent [5]. Further study is needed to elucidate the complicated
ociations between these adipokines and obesity paradox. These
ds are really interesting and will clarify the mechanisms of obe-
 paradox.
We  hope that our reply will address the problems that Dr Lin
gested. Once again, we  would like to thank you for your intel-
tual comments. We  would be most grateful if we  could continue
ave such a scientiﬁc discussion in future.
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